Contents

Search

alglucosidase alfa (Myozyme, Lumizyme)

Indications: - treatment of glycogen storage disease type-2 (Pompe disease) Dosage: - Dosage: - 20 mg/kg IV infusion every 2 weeks Monitor: - liver function tests baseline & periodically [2] Mechanism of action: - alpha-1,4-glucosidase

General

lysosomal alpha-glucosidase; alpha-1,4-glucosidase; acid alpha glucosidase; acid maltase (GAA) metabolic agent (metabolic modifier)

References

  1. UniProt :accession P10253
  2. Prescriber's Letter 17(7): 2010 Recommended Lab Monitoring for Common Medications Liver Function Test Scheduling Detail-Document#: 260704 (subscription needed) http://www.prescribersletter.com
  3. HIGHLIGHTS OF PRESCRIBING INFORMATION LUMIZYME (alglucosidase alfa). for injection, for intravenous use https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125291lbl.pdf